Get the Stockscreener App
36.92
0.60%
0.22
After Hours:
36.80
-0.12
-0.33%
Exelixis Inc stock is traded at $36.92, with a volume of 3.12M.
It is up +0.60% in the last 24 hours and down -4.57% over the past month.
See More
Previous Close:
$36.70
Open:
$36.23
24h Volume:
3.12M
Relative Volume:
1.26
Market Cap:
$10.31B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
23.67
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
-2.12%
1M Performance:
-4.57%
6M Performance:
+42.27%
1Y Performance:
+55.58%
1-Day Range:
$35.57
$37.12
1-Week Range:
$35.57
$38.41
52-Week Range:
$20.14
$40.02
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.92 | 10.31B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance
Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada
Citi maintains Buy on Exelixis stock with $45 target - Investing.com India
Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView
Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha
Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener
FDA approves new treatment for advanced neuroendocrine tumors - Investing.com
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
Proficio Capital Partners LLC Takes $706,000 Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace
Looking Into Exelixis's Recent Short Interest - Benzinga
Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st
Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN
Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Exelixis Growth Continues with Big Money Boosts - Yahoo Finance
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
What 25 Analyst Ratings Have To Say About Exelixis - Benzinga
Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts (NASDAQ:EXEL) - Seeking Alpha
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? - Yahoo
Exelixis at Leerink Global Healthcare Conference: Strategic Growth and Innovation - Investing.com UK
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Exelixis at Barclays Healthcare Conference: Strategic Pipeline Progress By Investing.com - Investing.com UK
Exelixis stock hits 52-week high at $39.3 amid robust growth - Investing.com Australia
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):